AllSci News
Takeda’s zasocitinib Phase 3 Psoriasis Data Show Strong Efficacy
Takeda’s investigational oral tyrosine kinase 2 (TYK2) inhibitor zasocitinib (TAK-279) delivered positive topline results in two pivotal Phase 3 trials in adults…
Insmed halts brensocatib rhinosusitis program after Phase 2b miss
New Jersey-based biotech Insmed Inc., announced that the Phase 2b BiRCh study assessing brensocatib in chronic rhinosinusitis without nasal polyps (CRSsNP) failed…
GSK’s Exdensur wins US FDA approval as twice-yearly biologic for severe eosinophilic asthma
GSK plc revealed US FDA approval for Exdensur (depemokimab-ulaa) as an add-on maintenance treatment for patients aged 12 years and older with…
Astellas/Pfizer’s Padcev plus Keytruda hits endpoints in latest Phase 3 for early-stage bladder cancer
Astellas Pharma Inc., and Pfizer Inc., unveiled positive topline results from a Phase 3 trial assessing the perioperative combination of Padcev (enfortumab…
Recludix’s oral STAT6 inhibitor enters clinic with FDA IND clearance
San Diego-based biotech Recludix Pharma revealed a successful Investigational New Drug (IND) application to the US FDA for REX-8756, a potent, selective…
Enhertu expands to first-line breast cancer in U.S.
The US FDA approved a new indication for AstraZeneca/Daiichi Sankyo’s antibody drug conjugate (ADC) Enhertu (fam-trastuzumab deruxtecan-nxki; T-DxD), for use in combination…
Sanofi’s tolebrutinib falls short in Phase III for primary progressive MS
Sanofi disclosed topline results from the PERSEUS Phase III study evaluating tolebrutinib in primary progressive multiple sclerosis (PPMS), revealing that the investigational…
Sanofi confirms delay to tolebrutinib’s FDA review in nrSPMS
Sanofi announced that the US FDA review of its investigational Bruton’s tyrosine kinase (BTK) inhibitor tolebrutinib for non-relapsing secondary progressive multiple sclerosis…
AllSci Launches Hypothesis Publishing: A Seamless Way to Share, Connect, and Advance Scientific Ideas
North Bethesda, MD — December 15, 2025 — AllSci, the AI-powered research and discovery platform transforming how scientific knowledge is created and…
Pfizer’s Tukysa posts Phase 3 win as first-line maintenance in HER2+ breast cancer
Pfizer Inc. reported detailed results from the Phase 3 HER2CLIMB-05 trial showing that adding Tukysa (tucatinib) to first-line maintenance therapy significantly prolonged…
Lilly’s triple agonist retatrutide drives up to 28.7% weight loss and pain relief in Phase 3 TRIUMPH-4
Eli Lilly and Company’s investigational triple hormone receptor agonist retatrutide delivered substantial weight loss and meaningful relief from osteoarthritis pain in the…
Roche trumpets 30% cut to recurrence risk in ER+ breast cancer for SERD giredestrant
Roche announced that its experimental oral selective estrogen receptor degrader (SERD), giredestrant, significantly reduced the risk of invasive disease recurrence or death…
J&J’s Tecvayli combo delivers “remarkable” Phase 3 results in 2nd-line r/r MM
Johnson & Johnson (J&J)’s investigational combination of Tecvayli (teclistamab-cqyv) plus Darzalex Faspro (daratumumab + hyaluronidase) has shown remarkable efficacy in the Phase…
Hemab’s sutacimig set to be first prophylaxis for Glanzmann thrombasthenia
Denmark-based Hemab Therapeutics announced that its Phase 2 study for sutacimig in Glanzmann thrombasthenia (GT) delivered strong, “clinically meaningful” reductions in treated…
Pfizer boasts strong data for Hympavzi in inhibitor-positive hemophilia
Pfizer reported new Phase 3 data showing that Hympavzi (marstacimab) reduced treated annualized bleeding rate (ABR) by 93% compared with on-demand bypassing…
The AllSci Brief
Systematic R&D and deal news. Daily.